Oral bisphosphonates are well established as a first -line option for the treatment of osteoporosis. Bisphosphonates inhibit bone resorption, increase bone mineral density (BMD) and decrease the risk of osteoporotic fractures.
For alendronate and risedronate, weekly administration is as effective as once daily dosing. More recently, a presentation of risedronate has become available in a format that allows treatment to be administered once a month, and it is expected that this will further improve ease of administration and patient compliance.
The 2009 RGH E-Bulletins are archived here.
If you like this post and what else you see on the blog please subscribe by RSS feed (the orange button) or by email. Visit my subscription page.
A joint initiative of the Patient Services Section and the Drug and Therapeutics Information Service of the Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia. The RGH Pharmacy E-Bulletin is distributed in electronic format on a weekly basis, and aims to present concise, factual information on issues of current interest in therapeutics, drug safety and cost-effective use of medications.
Editor: Assoc. Prof. Chris Alderman, University of South Australia – Director of Pharmacy, RGH © Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia 5041.
{ 0 comments }
